Following Kite's participation in the Series A round closed in March 2021, Kite (a Gilead Company - Nasdaq: GILD) and Shoreline enter into a strategic partnership, with a $60 million upfront payment and milestones and royalties payments worth up to $2.3 billion. Shoreline Biosciences was founded and seeded by Stork Capital in July 2020

Following the seed round funding by Stork Capital in July 2020, and the $43m Series A round closed in March 2021, Shoreline Biosciences announces its first major partnership.

Connect Biopharma lists on NASDAQ raising US$191.3m

Co-founded by Stork Capital and led by Stork Capital’s Life Sciences Chairman Kleanthis G. Xanthopoulos, Ph.D.